<unk>  (trade name Conmana) is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).<unk>  is approved for use in China as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations.
Icotinib
Tepotinib
Crizotinib
Nilotinib
Afatinib
Imatinib
Neratinib
Acalabrutinib